hotspot -WSS

hotspot

author：focus 2025-08-19 15:01:48 - browse：5

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — A newly approved Alzheimer’s drug made by Eisai and Biogen, called Leqembi, aims to clear out amyloid plaques in patients’ brains. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia.

The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies. Advocates had warned that could cause issues related to a new class of Alzheimer’s drugs designed to clear those plaques.

“We know there is significant interest in the medical community about new treatments that may be effective in slowing the development of Alzheimer’s disease. PET scans are an important part of diagnosis and treatment of Alzheimer’s disease,” Centers for Medicare and Medicaid Administrator Chiquita Brooks-LaSure said in a written statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Francis Collins on trust in science and how Covid communications failed

WSS

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

Eli Lilly, Pfizer, and others want in on the online prescription market

eGenesis tests gene

Dewpoint Therapeutics lays off staff after losing partnerships

Ph.D. graduate surprised with gift registry: 'You deserve to be celebrated'

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

leisure time

hotspot

focus

In age of alternative facts, a scholarly course on calling out crap

Biden's Plan B on student loan forgiveness relies on Higher Education Act: What to know

In Memoriam: Notable people who died in 2023

Readout Newsletter: Merck, J&J, and long Covid

Heart attack and stroke risk calculators need revising

Former New York Mayor de Blasio and wife announce separation, but not divorce

The cancer drug shortage isn’t new — and neither are the solutions

Suspect in Ukraine detonates explosives at a courthouse, killing himself and wounding 2 officers

Virginia high school admissions case could be legal follow

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

leisure time

eGenesis tests gene

Princess Kate attends Wimbledon with Roger Federer: See the photos

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

Condition critical? Britain's beloved but battered National Health Service turns 75

New brain studies show LSD's effects on the brain in full color

The surgeon had a dilemma only a Nazi medical text could resolve

focus

entertainment

focus

leisure time